Two distinct pathways account for EDHF-dependent dilatation in the gracilis artery of dyslipidaemic hApoB+/+ mice.
1 A universal endothelium-derived hyperpolarising factor (EDHF--non-NO/non-PGI(2)) has not been identified. EDHF, however, is essential for the physiological control of resistance artery tone. The impact of dyslipidaemia (DL), a risk factor for cardiovascular diseases, on the nature and the efficacy of EDHF has not been evaluated yet. 2 Pressurised (80 mmHg) gracilis arterial segments isolated from mice expressing the human apoB-100 and C57Bl/6 wild-type (WT) mice were used. EDHF-dependent dilatations to acetylcholine (ACh) were measured in the presence of L-NNA (100 microM, NOS inhibitor) and indomethacin (10 microM, COX inhibitor). 3 Maximal EDHF-induced dilatations were increased in DL when compared to WT (95+/-2 versus 86+/-4% in WT; P<0.05). Combination of apamin and charybdotoxin strongly reduced (P<0.05) ACh-induced dilatation in WT (22+/-4%) and DL (25+/-5%). 4 Combined addition of barium (Ba(2+)) and ouabain abolished EDHF-induced dilatations in WT arteries (13+/-3%; P<0.05). In vessels isolated from DL mice, however, only the addition of 14,15-EEZE (a 14,15-EET antagonist) to Ba(2+) and ouabain prevented EDHF-induced dilatations (5+/-3% compared to 54+/-11% in the presence of combined Ba(2+) and ouabain; P<0.05). 5 Our data suggest that EDHF-mediated dilatation depends on the opening of endothelial SK(Ca) and IK(Ca) channels. This is associated with the opening of K(ir) channels and activation of the Na(+)/K(+)-ATPase pump on smooth muscle cells leading to dilatation. In arteries from DL mice, a cytochrome P450 metabolite likely to be 14,15-EET equally contributes to the dilatory action of ACh. The early increased efficacy of EDHF in arteries isolated from DL mice may originate from the duplication of the EDHF pathways.
Krummen
Stéphane
S
Département de chirurgie et Groupe de Recherche sur le Système Nerveux Autonome, Institut de Cardiologie de Montréal, centre de recherche, Université de Montréal, Québec, Canada H1T 1C8.
Falck
John R
JR
Thorin
Eric
E
D000818:Animals; D053299:Apolipoprotein B-100; D001055:Apolipoproteins B / Q000235:genetics*; D001158:Arteries / Q000502:physiology; D001685:Biological Factors / Q000502:physiology*; D003577:Cytochrome P-450 Enzyme System / Q000502:physiology; D004730:Endothelium, Vascular / Q000502:physiology*; D011464:Epoprostenol / Q000502:physiology; D017629:Gap Junctions / Q000502:physiology; D006801:Humans; D006949:Hyperlipidemias / Q000378:metabolism / Q000503:physiopathology*; D066298:In Vitro Techniques; D051660:Intermediate-Conductance Calcium-Activated Potassium Channels; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D018482:Muscle, Skeletal / Q000098:blood supply*; D009569:Nitric Oxide / Q000502:physiology; D024681:Potassium Channels, Calcium-Activated / Q000502:physiology; D024661:Potassium Channels, Inwardly Rectifying / Q000502:physiology; D051640:Small-Conductance Calcium-Activated Potassium Channels; D000254:Sodium-Potassium-Exchanging ATPase / Q000502:physiology; D014655:Vascular Resistance; D014664:Vasodilation / Q000502:physiology*
D053299:Apolipoprotein B-100; D001055:Apolipoproteins B; D001685:Biological Factors; D051660:Intermediate-Conductance Calcium-Activated Potassium Channels; C496923:KCNN4 protein, human; C496925:Kcnn4 protein, mouse; D024681:Potassium Channels, Calcium-Activated; D024661:Potassium Channels, Inwardly Rectifying; D051640:Small-Conductance Calcium-Activated Potassium Channels; C067410:endothelium-dependent hyperpolarization factor; D009569:Nitric Oxide; D003577:Cytochrome P-450 Enzyme System; D011464:Epoprostenol; D000254:Sodium-Potassium-Exchanging ATPase